AUGUST 2010
August 26 2010- Preliminary 2010 Annual Report
August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy
23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.
16 August - Mesoblast on track for Phase 3 bone marrow transplant trial following positive meeting with FDA
JULY 2010
21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products
12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial
MAY 2010
28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders
19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion
12 May - Mesoblast to acquire Angioblast Systems Inc
APRIL 2010
30 April- Mesoblast Completes Enrolment for First Spinal Fusion Trial; Well Funded for Product Commercialisation
6 April – Mesoblast's Market Exclusivity for its Biologic Products Strengthened by New United States Health Care Act
MARCH 2010
3 March – Key Bone Repair Patent Granted in the United States
FEBRUARY 2010
February 25 - Mesoblast Half-Year Results
DECEMBER 2009
December 21 - Mesoblast - National Electronic Media Coverage
December 18 - Single Dose Of Proprietary Adult Stem Cells Regenerates Damaged Pancreas And Reduces Blood Glucose Levels In Diabetes
NOVEMBER 2009
November 30 - Executive Director’s Presentation to the 2009 Annual General Meeting
November 30 - A Year of Solid Progress – Mesoblast Chairman’s Address to the 2009 Annual General Meeting
November 18 - Sustained Six-Month Improvement In Heart Muscle Function By "Off-The-Shelf" Adult Stem Cells
November 06 - Successful Bone Marrow Regeneration In Cancer Patients Using Cord Blood Expanded By Proprietary Stem Cells
OCTOBER 2009
October 26 - Investor Briefing: The CEO Transcript
SEPTEMBER 2009
September 24 – UBS Life Sciences Investor Conference In United States Features Associate Company Angioblast
September 22 – Enrolment Complete For Second Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells
September 15 – Mesoblast Disc Repair Results Highlighted At Key Orthopaedic Conference
September 10 – Mesoblast's Proprietary Stem Cells Successfully Repair/Regenerate Damaged Intervertebral Disc Cartilage
September 01 – Investor Briefing - The CEO Transcript
AUGUST 2009
August 26 – Financial Year End Results. Mesoblast Delivers on Broadening Product Portfolio
August 25 – United States Associate Company Angioblast Closes $10M Equity-Based Financing
August 19 – Mesoblast's Associate Company, Angioblast Systems, Secures New Capital
August 17 – Mesoblast Gains US FDA Clearance For Phase 2 Trial In Minimally Invasive Lumbar Spinal Fusion Surgery
August 5 – Proprietary Technology In World First Allogenic Stem Cell Trial For Treatment of End-Stage Heart Failure In Patients Supported By Mechanical Heart Assist Devices
JULY 2009
July 30 – Strong Cash Position at End of Financial Year
July 23 - Mesoblast to Apply For Regulatory Approval Of Its Bone Fracture Repair Products
JUNE 2009
June 26 - Mesoblast Featured on ABC-TV's Catalyst Program
June 24 - First Patients In Bone Marrow Transplant Trial Show Earlier Engraftment. Potential For Accelerated Phase 3 Program
MAY 2009
May 14 - Heart Muscle Function Improved After Single Lowest-Dose Injection of "Off-The-Shelf" Stem Cells In Patients With Heart Failure
APRIL 2009
April 28 - Mesoblast Commences Clinical Program For Fusion Of Cervical Spine
MARCH 2009
March 30 - Mesoblast Raises Capital For New Clinical Programs
FEBRUARY 2009
February 27 - Mesoblast Results Highlighted At Key Orthopaedic Conferences
February 26 - Emerging Portfolio of Clinical Products Underpin Commercial Strategic Objectives
February 26 - Half Year Report
February 25 - First Group Of Heart Failure Patients with "Off-The-Shelf" Adult Stem Cells Successfully Pass Key Safety Milestone
February 16 - ParkwayHealth and Mesoblast To Provide Cutting Edge Treatment Using Proprietary Adult Stem Cells
JANUARY 2009
January 20 - Mesoblast Stem Cells Approved For World First Osteoarthritis Clinical Trial
January 06 - Mesoblast Named 2009 North American Emerging Company By Frost And Sullivan
NOVEMBER 2008
November 27 - Executive Director's Presentation at the AGM
November 27 - November 27 - Chairman's speech at AGM
November 24 - Investor Briefing – The CEO Transcript
November 14 - Frost & Sullivan Selects Proprietary Technology Platform as U.S. Stem Cell Market Innovation Of The Year
November 11 - Proprietary Stem Cells For Heart Failure Highlighted At Major Cardiology Conference in United States
November 07 - Mesoblast Featured At UBS Healthcare Investor Conference
November 05 - Bone Marrow Transplant Trial Using Proprietary Cell Therapy Receives United States FDA Clearance And Institutional Ethics Approval
OCTOBER 2008
October 13 - First Heart Failure Patients Successfully Implanted in United States
SEPTEMBER 2008
September 25 - UBS Life Sciences Investor Conference Features Angioblast
September 23 - Mesoblast Commercial Leadership Featured At World Stem Cell Summit
September 17 - FDA Grants Orphan Drug Designation For Use of Proprietary Stem Cells in Bone Marrow Transplants
AUGUST 2008
August 28 - Mesoblast Reports Significant Achievements and Strong Financial Position
August 21 - Mesoblast's Allogeneic "Off -The-Shelf" stem cells are safe and effective for Cervical Spine Fusion
August 12 - Mesoblast's Stem Cells Regrow Knee Cartilage in Severe Post-Menopausal Osteoarthritis
August 07 - Mesoblast - National Electronic Media coverage
August 06 - Non-Healing Bones Repaired in Clinical Trial using Adult Stem Cells
JULY 2008
July 30 - Sky Business News – Interview with Executive Director & Founder Professor Silviu Itescu
July 21 - Investor Briefing – The CEO Transcript
July 16 - Key Stem Cell Patent Granted In United States. Ensures Long-Term, Exclusive Rights and Underpins Commercial Opportunities.
July 10 - Allogenic Stem Cells Effectively Treat Eye Diseases
JUNE 2008
June 05 - United States FDA Clears Phase 2 Trial for Congestive Heart Failure. Major new market opportunity
APRIL 2008
April 17 - Mesoblast's cells show long-lasting and sustained effect in knee osteoarthritis
April 09 - Spinal Fusion Clinical Program Update - Accelerated Timetable to Registration Trial
April 07 - U.S. Heart Attack Trial Update - "Most Exciting Stem Cell Therapy in Heart Research Today"
FEBRUARY 2008
February 27 - Mesoblast Half Year Results. Company well resourced to execute clinical and commercial strategic objectives
February 19 - Agreement with Abbott for Catheter-Based Stem Cell Heart Failure Therapy
February 13 - Highly successful results of bone repair trial show that Mesoblast's stem cells promote and repair fracture healing
DECEMBER 2007
December 10 - Mesoblast raises new capital to expand clinical programs
NOVEMBER 2007
November 21 - AGM Address by Chairman
November 21 - Mesoblast Appoints New Non-Executive Chairman
OCTOBER 2007
October 30 - Former Johnson & Johnson Vice Chairman joins Angioblast Board of Directors
SEPTEMBER 2007
September 27 - Angioblast featured at UBS Global Life Sciences Conference in New York. Company unveils major new program in eye disease.
AUGUST 2007
August 30 - Financial year end results. Mesoblast advances into Phase 2 trials
August 29 - Mesoblast national television coverage
August 20 - Mesoblast's stem cells protect knee cartilage in osteoarthritis
August 10 - Successful clinical outcomes in Stem Cell Heart Trial. Heart muscle recovery shown in all patients
JULY 2007
July 27 - Change in executive chairman's role
July 24 - Mesoblast commences vertebral disc cartilage program to target early disease
July 16 - Mesoblast moves forward with the next phase of clinical trials using "off-the-shelf" stem cells
JUNE 2007
June 18 - Mesoblast announces strong interim results in fracture repair trial
MAY 2007
May 02 - FDA Clearance Received For Heart Attack Stem Cell Clinical Trial
APRIL 2007
April 02 - FDA submission filed for clinical trial of stem cells in heart attack patients
MARCH 2007
March 07 - Mesoblast's road to United States product registration
FEBRUARY 2007
February 20 - Mesoblast well funded for clinical trials
February 09 - Sale of shares
February 06 - Stem cell patents granted for Cardiac Disease and new clinical opportunities
DECEMBER 2006
December 18 - Mesoblast receives FDA clearance for Phase 2 stem cell clinical trial
December 04 - Mesoblast television coverage
NOVEMBER 2006
November 23 - Executive Chairman Speech to AGM/EGM
November 21 - Mesoblast files FDA submission
November 14 - Stem cell heart attack trial produces positive preclinical results
OCTOBER 2006
October 18 - Major Stem Cell patent granted in United States ensures exclusive, long-term commercial rights
SEPTEMBER 2006
September 21 - Further investment in Angioblast to complete a phase II Cardiovascular Trial
September 19 - Heart function improves in stem cell trials
September 13 - Financial year results: continued focus on rapid commercialisation of adult stem cells
AUGUST 2006
August 22 - Stem cell bone repair trials produce outstanding results
August 15 - Mesoblast shareholders show strong support for share purchase plan
JULY 2006
July 31 - Mesoblast advances to new level of commercialisation
20 July 2006
Mesoblast locks in capital to drive next stage of commercialisation and growth
04 July 2006
Mesoblast targets major cartilage markets: Osteoarthritis & Sports Injuries
JUNE 2006
07 June 2006
Mesoblast achieves major milestones: positive results accelerate product commercialisation
01 June 2006
Transcript ABC-TV CATALYST Program
MAY 2006
22 May 2006
Positive results in preclinical trial for heart failure
16 May 2006
Significant progress toward achieving clinical trial goals
APRIL 2006
28 April 2006
Mesoblast announces strong cash position for adult stem cell commercialisation
27 April 2006
Positive results confirm spinal fusion as major market for Mesoblast
06 April 2006
National TV coverage of first orthopaedic trial
03 April 2006
First patient receives adult stem cells for repair of long bone fracture
MARCH 2006
24 March 2006
Boardroom Radio - Interview with Executive Chairman, Mr Michael Spooner
22 March 2006
Next Generation Drug Eluting Stent Technology For
Coronary And Peripheral Artery Disease
13 March 2006
Mesoblast releases half-year financial report
08 March 2006
Mesoblast national television coverage
FEBRUARY 2006
28 February 2006
Mesoblast well ahead of schedule
13 February 2006
Pre-clinical studies validate universal donor business model
06 February 2006
First two patients safely implanted with adult stem cells
JANUARY 2006
31 January 2006
Mesoblast announces strong cash position for adult stem cell clinical program
17 January 2006
Key Australian adult stem cell patent granted
DECEMBER 2005
21 December 2005
Australian Government awards Mesoblast $2.7M for treatment of arthritic and other cartilage diseases
19 December 2005
Adult Stem Cell Heart Trial Update
07 December 2005
First Patients Recruited For Mesoblast Pilot Clinical Trials
NOVEMBER 2005
15 November 2005
ASX Announcement: 2006 TO BE AN EXTRAORDINARY YEAR. Patient Recruitment for Adult Stem Cell Trials Commenced
15 November 2005
Annual General Meeting Address to Shareholders by Executive Chairman Michael Spooner
07 November 2005
Mesoblast and Cordis Corporation to join forces in Adult Stem Cell Heart Trial
OCTOBER 2005
19 October 2005
Mesoblast highlighted at premier global stem cell conference
17 October 2005
Mesoblast outlines accelerated timetable for clinical trials and regulatory approvals
14 October 2005
Mesoblast 2005 Annual Report
14 October 2005
Notice of 2005 Annual General Meeting
14 October 2005
Explanatory notes – 2005 Annual General Meeting
13 October 2005
Mesoblast Investor update presentation summary
13 October 2005
Mesoblast Investor update presentation
7 October 2005
Mesoblast makes key advisory appointments
SEPTEMBER 2005
23 September 2005
World first adult stem cell trial approved by Royal Melbourne Hospital for orthopaedic use
20 September 2005
Mesoblast initiates commercial production of adult stem cells
13 September 2005
Mesoblast announces financial year results
05 September 2005
Mesoblast adult stem cell technology highlighted in inaugural edition of Forbes Asia magazine
AUGUST 2005
29 August 2005
Mesoblast commences bone regeneration trials at Colorado State University
24 August 2005
Mesoblast signs agreement with major international medical company
15 August 2005
Mesoblast appoints Michael Spooner as Executive Chairman
JULY 2005
21 July 2005
Colorado State University to trial Mesoblast's universal donor adult stem cells for bone regeneration
5 July 2005
Mesoblast targets United States Investor Base
JUNE 2005
14
June 2005
Mesoblast makes key clinical affairs appointment
03 June 2005
Potential For Use Of Mesoblast’s Cell Therapy In Treatment Of Sports Injuries
APRIL 2005
29 April 2005
Mesoblast cash reserves over $16 million
29 April 2005
Appendix 4C Quarterly report for entities admitted on the basis of commitments
19 April 2005
Human trial of adult stem cells approved by Ethics Committee
MARCH 2005
31 March 2005
Mesoblast makes rapid progress towards adult stem cell clinical trials
15 March 2005
$1.5 million stem cell grant
FEBRUARY 2005
28
February 2005
Half Year Report - Appendix 4D
28
February 2005
Half Year Results
15 February 2005
Mesoblast contacts cell processing facility for pilot clinical trials
DECEMBER 2004
16 December 2004
Adult stem cell company Mesoblast lists at 82% premium
8 December 2004
Mesoblast $21M IPO to commercialise world leading adult stem cell technology
News Room
|
